‘Sand, Snow, and Stardust' Review: When the Battlefield Fights Back
When Allied troops landed in North Africa in November 1942, they expected blistering heat and endless sand. What they found was thigh-deep mud, torrential rains and bitterly cold temperatures. If, as they say, no battle plan survives first contact, the Allies' first defeat was at the hands of the weather.
'It was hard to square what the GIs had been told with the reality they found on the ground,' writes Gretchen Heefner in 'Sand, Snow, and Stardust: How U.S. Military Engineers Conquered Extreme Environments.' Brig. Gen. Theodore Roosevelt III, the son of President Theodore Roosevelt, 'openly mocked pamphlets that had promised sunshine and warmth,' we learn. 'With 'customary dumbness,' he declared, the military had considered all of Africa a 'tropical country.''
The experience of having to fight the climate as well as the Germans launched a decadeslong effort by the U.S. military and its scientific partners to better understand the harsh environments our troops would face in future wars. American engineers and construction workers encountered similar challenges in building the post-World War II Pax Americana of permanent U.S. military bases around the world.
'It is difficult for us to grasp just how little was understood about the world's most out-of-the-way places' in the mid-20th century, writes Ms. Heefner, a professor of history at Northeastern University and the author of 'The Missile Next Door: The Minuteman in the American Heartland' (2012). 'Wartime needs put in motion a spectacularly broad effort to collect information about places that were considered unknowable.' The military was smart enough to realize it not only didn't have all the answers, it didn't even know what the questions were. So it turned to a broad array of civilian experts. 'Academics who had traipsed across the world's deserts to look for new species and adventurers who had spent months riding sledges in the Arctic,' we are told, 'all found wartime homes in the research centers that were created to account for the unfamiliar.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Boston Globe
3 hours ago
- Boston Globe
From no hope to a potential cure for a deadly blood cancer
A third responded so well that they got what seems to be an astonishing reprieve. The immunotherapy developed by Legend Biotech, a company founded in China, seems to have made their cancer disappear. And after five years, it still has not returned in those patients -- a result never before seen in this disease. Advertisement These results, in patients whose situation had seemed hopeless, has led some battle-worn American oncologists to dare to say the words 'potential cure.' Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up 'In my 30 years in oncology, we haven't talked about curing myeloma,' said Dr. Norman Sharpless, a former director of the National Cancer Institute who is now a professor of cancer policy and innovation at the University of North Carolina School of Medicine. 'This is the first time we are really talking seriously about cure in one of the worst malignancies imaginable.' The new study, reported Tuesday at the annual conference of the American Society of Clinical Oncology and published in The Journal of Clinical Oncology, was funded by Johnson & Johnson, which has an exclusive licensing agreement with Legend Biotech. The 36,000 Americans who develop multiple myeloma each year face an illness that eats away at bones, so it looks as if holes have been punched out in them, said Dr. Carl June, of the University of Pennsylvania. Bones collapse. June has seen patients who lost 6 inches in height. Advertisement 'It's a horrible, horrible death,' June said. 'Right now advanced myeloma is a death sentence.' (June has immunotherapy patents that are owned by his university.) There have been treatment advances that increased median survival from two years to 10 over the past two decades. But no cures. Dr. Peter Voorhees of the Atrium Health Levine Cancer Institute in North Carolina and the Wake Forest University School of Medicine, who is lead researcher for the newly published study, said patients usually go through treatment after treatment until, ultimately, the cancer prevails, developing resistance to every class of drug. They end up with nothing left to try. The Legend immunotherapy is a type known as CAR-T. It is delivered as an infusion of the patient's own white blood cells that have been removed and engineered to attack the cancer. The treatment has revolutionized prospects for patients with other types of blood cancer, like leukemia. Making CAR-T cells, though, is an art, with so many possible variables that it can be hard to hit on one that works. And it can have severe side effects including a high fever, trouble breathing and infections. Patients can be hospitalized for weeks after receiving it. But Legend managed to develop one that works in multiple myeloma, defying skeptics. The Chinese company gained attention for its CAR-T eight years ago when it made extravagant claims, which were met by snickers from American researchers. Advertisement Johnson & Johnson, though, was looking for a CAR-T to call its own. So, said Mark Wildgust, an executive in the oncology section of the American drug giant, the company sent scientists and physicians to China to see if the claims were true. 'We went site by site to look at the results,' he said. The company was convinced. It initiated a collaboration with Legend and began testing the treatment in patients whose myeloma had overcome at least one standard treatment. Compared with patients who had standard treatment, those who had the immunotherapy lived longer without their disease progressing. The immunotherapy received regulatory approval in that limited setting and is sold under the brand name Carvykti. The study did not determine whether this difficult treatment saved lives. The new study took on a different challenge -- helping patients at the end of the line after years of treatments. Their immune systems were worn down. They were, as oncologists said, 'heavily pretreated.' So even though CAR-T is designed to spur their immune systems to fight their cancer, it was not clear their immune systems were up to it. Oncologists say that even though most patients did not clear their cancer, having a third who did was remarkable. To see what the expected life span would be for these patients without the immunotherapy, Johnson & Johnson looked at data from patients in a registry who were like the ones in its study -- they had failed every treatment. They lived about a year. For Anne Stovell of New York, one of the study patients whose cancer disappeared, the result is almost too good to be true. She says she went through nine drugs to control her cancer after it was diagnosed in 2010, some of which had horrendous side effects. Each eventually failed. Advertisement Taking the Legend CAR-T was difficult -- she said she had spent nearly three weeks in the hospital. But since that treatment six years ago, she has no sign of cancer. She said it was still difficult for her to believe her myeloma is gone. A new ache -- or an old one -- can bring on the fear. 'There's that little seed of doubt,' she said. But in test after test, the cancer has not reappeared. 'It's a relief for me every year to get a bone marrow biopsy,' she said. Myeloma experts applauded the results. Like treatments for many other cancers, treatments for multiple myeloma come with a high price. The drugs are 'hideously expensive,' June said, costing more than $100,000 a year. The total cost over the years can be millions of dollars, June said, usually paid by insurers, 'and it doesn't even cure you.' CAR-T is expensive too. Carvykti's list price is $555,310. But it is a one-time treatment. And, more important, the hope is that perhaps by giving it earlier in the course of the disease, it could cure patients early on. Johnson & Johnson is now testing that idea. Dr. Kenneth Anderson, a myeloma expert at Dana-Farber Cancer Institute who was not involved with the study, said that if the treatment is used as a first-line treatment, 'cure is now our realistic expectation.' That, at least, is the hope, Sharpless said. And for those like the patients in the new study who are living at least five years -- so far -- without disease, the outcome 'really is eye-popping,' Sharpless said. Advertisement 'That's getting to a point where you wonder if it will ever come back,' he added. This article originally appeared in
Yahoo
5 hours ago
- Yahoo
Eating this popular fruit daily may support postmenopausal heart and metabolic health
Eating fresh mango every day may help to boost women's postmenopausal heart and metabolic health, researchers said Tuesday. They found that eating about 1.5 cups of the sweet fruit a day for two weeks significantly reduced blood pressure and cholesterol among postmenopausal women living with obesity. Both blood pressure and cholesterol are key indicators of heart health. 'Risk factors like high blood pressure and unhealthy cholesterol are key contributors to cardiovascular disease, but a nutrient-rich diet that includes fresh fruit, like mango, has long been shown to help reduce those risks,' Dr. Roberta Holt, an associate researcher at UC Davis, said in a statement. 'This study shows that even short-term changes — like eating fresh mangos daily — can make a measurable impact on chronic disease risk in certain populations.' Holt was a co-author of the research which was published Tuesday in the Journal of the American Nutrition Association. The study was supported through an unrestricted grant from the National Mango Board, although the board had no influence over the study. To reach these conclusions, they examined the health of 24 women between the ages of 50 to 70 years old who were overweight or obese. Before the study period, the authors instructed them to refrain from eating mangos. Over two weeks, the researchers collected baseline measurements, measurements when consumption began during a second visit to their lab, and then more measurements at the third visit. The women ate mangos in the mornings and the evenings. Two hours after consumption, their resting blood pressure dropped and there was a reduction in average arterial pressure. After consuming mangos every day for two weeks, their total cholesterol was slashed by nearly 13 points and their bad cholesterol dropped by the same amount. A smaller follow-up with just six participants from the initial study examined insulin and sugar levels after eating the same amount of mango with 83 grams of white bread. The researchers found the women's blood sugar levels rose significantly less after eating mango than after eating white bread. Insulin levels also responded more favorably to mango. Although mangos are high in natural sugar compared to other fruits, they also provide crucial vitamins and other nutrients. Additional research is needed to determine the effects of mango consumption of heart and metabolic health, but the benefits could aid the 1.3 million U.S. women undergoing menopause: a period when the risk of heart disease rises significantly. Women spend up to 40 percent of their lives in this life stage, and nearly half of American women are affected by cardiovascular disease. 'Post-menopausal women face distinct metabolic changes that can impact their risk of developing cardiovascular disease,' said Holt. 'These findings help to identify targeted dietary strategies, like eating fresh mangos daily, to aid this at-risk population and support cardiovascular wellness and potential reductions in chronic disease risk.'
Yahoo
6 hours ago
- Yahoo
Chinese nationals charged with smuggling fungus into Michigan
LANSING, Mich. (WLNS) — In Detroit, two people were charged with allegedly smuggling a fungus into America, claiming it was for studying at the University of Michigan, according to the U.S. Attorney's Office, Eastern District of Michigan. United States Attorney Jerome F. Gorgon Jr. reports that Yunqing Juan, 33, and Zunyong Liu, 34, citizens of the People's Republic of China, were charged with a criminal complaint with conspiracy, smuggling goods into the United States, false statements, and visa fraud. According to the complaint, Liu initially lied but later admitted to smuggling the fungus into America through the Detroit Metropolitan Airport so that he could conduct research with his girlfriend at a laboratory at the University of Michigan. The fungus called Fusarium graminearum is the most significant and destructive disease affecting wheat crops all over the world, according to the National Library of Medicine. The scientific literature classifies it as a potential agroterrorism weapon. According to the FBI, the complaint reports Jian received Chinese government funding for her work on this pathogen in China. The complaint also alleges that Jian's electronics have information about her loyalty to the Chinese Communist Party. Jian's boyfriend, Liu, researches the same pathogen at a Chinese University. 'The alleged actions of these Chinese nationals—including a loyal member of the Chinese Communist Party—are of the gravest national security concerns. These two aliens have been charged with smuggling a fungus that has been described as a 'potential agroterrorism weapon' into the heartland of America, where they apparently intended to use a University of Michigan laboratory to further their scheme,' said United States Attorney Gorgon. 'Today's criminal charges levied upon Yunqing Jian and Zunyong Liu are indicative of CBP's critical role in protecting the American people from biological threats that could devastate our agricultural economy and cause harm to humans; especially when it involves a researcher from a major university attempting to clandestinely bring potentially harmful biological materials into the United States. This was a complex investigation involving CBP offices from across the country, alongside our federal partners. I'm grateful for their tireless efforts, ensuring our borders remain secure from all types of threats while safeguarding America's national security interests,' said U.S. Customs and Border Protection Director of Field Operations Marty C. Raybon. JianDownload This case is still under investigation, United States Attorney Gorgon reports. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
